Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMHTG8P)

Drug Name
TP-0903 Drug Info
Synonyms
YUAALFPUEOYPNX-UHFFFAOYSA-N; 1341200-45-0; TP0903; UNII-14D65TV20J; CHEMBL2022968; compound 13; 14D65TV20J; TP 0903; 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide; GTPL8863; SCHEMBL12813478; EX-A609; MolPort-039-193-844; ZINC84617535; BDBM50382425; AKOS026750306; CS-4281; DA-45909; HY-12963; S7846; FT-0700169; B5940; J-690134; 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide
Cross-matching ID
PubChem CID
56839178
ChEBI ID
CHEMBL2022968
CAS Number
CAS 1341200-45-0
TTD Drug ID
D00LGR

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Complement and coagulation cascades 2.37 0.00e+0 76/85 (89.41%) SERPING1;CLU;SERPINA1;...
Lysosome 2.26 0.00e+0 115/128 (89.84%) GM2A;LIPA;MAN2B1;...
Type I diabetes mellitus 2.20 0.00e+0 38/43 (88.37%) HLA-DQA1;HLA-B;CPE;...
Phagosome 2.19 0.00e+0 118/152 (77.63%) HLA-DQA1;SCARB1;HLA-B;...
Graft-versus-host disease 2.15 0.00e+0 32/42 (76.19%) HLA-DQA1;HLA-B;HLA-F;...
Viral myocarditis 2.11 0.00e+0 53/60 (88.33%) HLA-DQA1;HLA-B;SGCB;...
Valine, leucine and isoleucine degradation 2.06 0.00e+0 42/48 (87.5%) OXCT1;ALDH6A1;ACADM;...
Rheumatoid arthritis 2.05 0.00e+0 78/93 (83.87%) CCL20;HLA-DQA1;CXCL8;...
Glycosaminoglycan degradation 2.03 1.54e-3 19/19 (100%) HEXA;GUSB;HEXB;...
Allograft rejection 1.95 2.77e-3 32/38 (84.21%) HLA-DQA1;HLA-B;HLA-F;...
Other glycan degradation 1.94 3.78e-3 13/18 (72.22%) MAN2B1;MAN2B2;HEXA;...
Autoimmune thyroid disease 1.93 4.62e-3 46/53 (86.79%) HLA-DQA1;HLA-B;HLA-F;...
ECM-receptor interaction 1.93 4.26e-3 80/88 (90.91%) THBS2;COL1A2;ITGB5;...
Various types of N-glycan biosynthesis 1.87 5.94e-3 26/39 (66.67%) DDOST;HEXA;MAN2A1;...
Tryptophan metabolism 1.85 5.54e-3 35/42 (83.33%) MAOA;IDO1;HADH;...
Vitamin digestion and absorption 1.85 6.06e-3 17/24 (70.83%) SCARB1;ABCC1;TCN2;...
Pertussis 1.84 5.70e-3 64/76 (84.21%) SERPING1;CXCL8;C2;...
Propanoate metabolism 1.83 8.47e-3 30/34 (88.24%) ALDH6A1;SUCLG2;PCCB;...
Pentose phosphate pathway 1.81 1.02e-2 25/30 (83.33%) RPIA;TKTL1;FBP1;...
Chemokine signaling pathway 1.76 1.45e-2 163/192 (84.9%) CCL20;CXCL8;RHOA;...
Cholesterol metabolism 1.74 1.78e-2 44/50 (88%) LRPAP1;SCARB1;LIPA;...
Relaxin signaling pathway 1.72 2.02e-2 114/129 (88.37%) MMP9;COL1A2;CREB1;...
Fatty acid degradation 1.70 2.29e-2 40/43 (93.02%) ACSL1;ACADM;HADH;...
Cell adhesion molecules 1.70 2.25e-2 118/148 (79.73%) SDC2;HLA-DQA1;HLA-B;...
Leukocyte transendothelial migration 1.69 2.38e-2 90/114 (78.95%) MMP9;CYBA;THY1;...
Human cytomegalovirus infection 1.69 2.29e-2 201/225 (89.33%) PDGFRA;CXCL8;HLA-B;...
Antigen processing and presentation 1.68 2.31e-2 60/78 (76.92%) HLA-DQA1;HLA-B;PSME1;...
Nitrogen metabolism 1.65 2.97e-2 16/17 (94.12%) GLUL;GLUD2;CA12;...
Butanoate metabolism 1.63 3.30e-2 23/28 (82.14%) OXCT1;ALDH5A1;HADH;...
Glycine, serine and threonine metabolism 1.62 3.69e-2 31/40 (77.5%) MAOA;ALDH7A1;SDS;...
Pyrimidine metabolism -1.72 3.43e-2 40/56 (71.43%) NUDT2;ENPP1;NME3;...
Cell cycle -1.74 2.91e-2 110/124 (88.71%) BUB1;CCNA1;PLK1;...
RNA transport -1.92 2.04e-3 128/186 (68.82%) GLE1;NUP58;NXT2;...
Spliceosome -1.95 0.00e+0 101/150 (67.33%) DDX5;RBMX;HNRNPU;...
Ribosome biogenesis in eukaryotes -2.14 0.00e+0 52/108 (48.15%) NXT2;IMP4;RCL1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-1-A CVCL_0293 Homo sapiens 3.33uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 3.33uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 3.33uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 3.33uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM 24H